1. [P4–567]: A PHASE 1 SAFETY TRIAL OF THE Aβ OLIGOMER RECEPTOR ANTAGONIST CT1812. (1st July 2017) Authors: Catalano, Susan; Grundman, Michael; Schneider, Lon S.; DeKosky, Steven; Morgan, Roger; Guttendorf, Robert; Higgin, Michelle; Pribyl, Julie; Mozzoni, Kelsie; Izzo, Nicholas J.; Safferstein, Hank Journal: Alzheimer's & dementia Issue: Volume 13:Supplement 7S(2017)Part 32 Page Start: P1570 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P4‐381: A Two‐Part, Double‐Blind, Placebo‐Controlled, Phase 1 Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of CT1812 in Healthy Volunteers. (1st July 2016) Authors: Catalano, Susan; Grundman, Michael; Schneider, Lon S.; DeKosky, Steven; Morgan, Roger; Higgin, Michelle; Pribyl, Julie; Mozzoni, Kelsie; Izzo, Nicholas J.; Safferstein, Hank; Lickliter, Jason Journal: Alzheimer's & dementia Issue: Volume 12:Supplement 7S(2014)Part 24 Page Start: P1183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P4‐708: CLINICAL BIOMARKER EVIDENCE FOR TARGET ENGAGEMENT, REDUCTION OF SYNAPTIC DAMAGE AND DISEASE MODIFICATION IN ALZHEIMER'S PATIENTS TREATED WITH CT1812. (1st July 2019) Authors: Schneider, Lon S.; Caggiano, Anthony O.; Grundman, Michael; DeKosky, Steve; Morgan, Roger; Mozzoni, Kelsie; Izzo, Nicholas J.; Safferstein, Hank; Catalano, Susan Journal: Alzheimer's & dementia Issue: Volume 15:Supplement 7S(2019)Part 31 Page Start: P1603 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. S2‐02‐03: PROGRESSION OF SYNAPTOPROTECTIVE SIGMA‐2 ANTAGONISTS INTO THE CLINIC. (1st July 2006) Authors: Catalano, Susan Journal: Alzheimer's & dementia Issue: Volume 14:Supplement 7(2018)Part 11 Page Start: P601 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗